1 Centre for Intellectual Property and Policy (CIPP), Faculty of Law, McGill University; Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada
2 Centre for Intellectual Property and Policy (CIPP), Faculty of Law, McGill University; Tanenbaum Open Science Institute (TOSI), Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
3 F1000, London, UK
4 Diseases of the Developing World, Global Health R&D, GlaxoSmithKline, Madrid, Spain
5 Fundação Oswaldo Cruz - Fiocruz, Rio de Janeiro, RJ, Brazil
6 Wellcome Trust,UK, London, UK
7 Montreal Neurological Institute and Hospital, Montreal, QC, Canada
8 US Department of Agriculture Economic Research Service, Washington, DC, USA
9 Health Research Board, Dublin, Ireland
10 School for the Future of Innovation in Society, Arizona State University, Washington, DC, USA
11 Sage Bionetworks, Seattle, WA, USA
12 US National Library of Medicine, Bethesda, MD, USA
13 Research England, UK Research and Innovation, Bristol, UK
14 Jisc, Bristol, UK
15 Centre for Intellectual Property and Policy (CIPP), Faculty of Law, McGill University, Montreal, QC, Canada
16 Queensland University of Technology; The Lens, Brisbane, QLD, Australia
17 The Lens, Canberra, ACT, Australia
18 African Academy of Sciences, Karen, Nairobi, Kenya
19 Utrecht University Library, Utrecht, UT, The Netherlands
20 Structural Genomics Consortium, University of Oxford, Oxford, UK
21 Data Science Institute, University of Virginia, Charlottesville, VA, USA
22 University of Cambridge, Cambridge, UK
23 Alkermes, Waltham, MA, USA
24 Center for Open Science (COS), University of Virginia, Charlottesville, VA, USA
25 Element AI, Montreal, QC, Canada
26 GlaxoSmithKline, Stevenage, UK
27 Warwick Research in Nursing, University of Warwick Medical School, Coventry, UK
28 University of Wolverhampton, Wolverhampton, UK
All commenters must hold a formal affiliation as per our Policies. The information that you give us will be displayed next to your comment.
User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.
Last Updated: 2 October 2017
Last Updated: 2 October 2017
Gates Open Research is an open access publishing platform controlled by the Bill & Melinda Gates Foundation (“Foundation”). This website, https://GatesOpenResearch.org (“Website”), is hosted and operated by F1000 Research Limited (“Service Provider”) on behalf of the Foundation.
BY CHECKING THE BOX NEXT TO “I ACCEPT THE USER COMMENT TERMS AND CONDITIONS” BEFORE YOU SUBMIT YOUR FIRST USER COMMENT, YOU AGREE TO BE BOUND BY THE GENERAL TERMS AND CONDITIONS AND THESE ADDITIONAL TERMS AND CONDITIONS EVERY TIME YOU SUBMIT A USER COMMENT. PLEASE DO NOT SUBMIT A USER COMMENT ON THIS WEBSITE IF YOU DO NOT AGREE TO THESE TERMS AND CONDITIONS. TERMS NOT DEFINED IN THESE ADDITIONAL TERMS AND CONDITIONS SHALL HAVE THE MEANING PROVIDED IN THE GENERAL TERMS AND CONDITIONS.